When GlaxoSmithKline (GSK) purchased Tesaro for $5 billion last December, one of the company’s big arguments in favor of the deal was that Tesaro’s lead drug, Zejula, would be useful in many more cancers than investors expected.

Zejula, like Lynparza from AstraZeneca and Merck, inhibits an enzyme called PARP, which is involved in repairing DNA. So far, it has proved useful mainly in cancers that are caused by mutations in the BRCA gene, the same one that causes breast and ovarian cancer. But Glaxo argued that there are cancers where Zejula would work, which also means a larger group of patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy